The role of pharmacy technicians, the naming of biosimilar drugs, and the appropriate use of testosterone are the three major issues that will be discussed during the American Society of Health-System Pharmacists’ (ASHP) first virtual House of Delegates meeting.
The first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.
While biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.